Pacific Biosciences of California, Inc. (PACB)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 9 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Pacific Biosciences’ second fiscal quarter of 2026 results missed consensus on both revenue and EPS, as reported August 3, 2026, with revenue down ~2% year over year to about $39.0 million. The company posted EPS of -$0.14, down ~8% from -$0.13 a year ago, and it trailed the -$0.13 estimate by $0.01, while revenue of $39.0 million trailed the $42.9 million estimate (-9.1%). Profitability remained pressured, with gross profit of roughly $12.6 million translating to a gross margin of about 32.4%, and operating income of about -$44.6 million implying an operating margin near -114.4%. Net income was about -$44.7 million, down ~7% from roughly -$41.9 million in the year-ago quarter. Consensus for the next period calls for EPS of -$0.13 on revenue of $43.8 million.
Next report — what to expect
Pacific Biosciences of California, Inc. (PACB) reports on November 3, 2026. For the upcoming quarter, consensus calls for EPS of -$0.126 on revenue of $43.8 million. As trailing context, revenue fell -1.9% year over year last quarter. PACB has beaten EPS in 4 of 8 most recent quarters.
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (NASDAQ: PACB) makes genetic sequencing instruments and related consumables for the medical technology market. Its PacBio Sequencing Systems sit at the center of the business, which generated $160.0 million in FY2025 revenue. The company was founded in 2000 and is based in Menlo Park, California.
Today's Snapshot
The day ended with PACB 2.4% higher at 2.11, outperforming a weaker sector. Trading was lighter than usual, with volume about half of its usual level. Earnings are due from PACB on 3 November.
Trading Volume
Below 10d avg (10.1M)
5.4M
vs S&P 500 Today
Outperforming Market
+2.95%
Updated: October 23, 2026 at 20:09 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.68 - $2.06Buy
- RSI (14)54.71Neutral
- Stochastic %K (14, 3, 3)23.18Neutral
- MACD Level (12, 26)0.08Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.